Eslicarbazepine acetate (BIA 2-093)

DRUG5 trials

Sponsors

Bial - Portela C S.A.

Conditions

EpilepsyPainful Diabetic NeuropathyPartial EpilepsyPartial Epilepsy in Children and AdolescentsPost Herpetic Neuralgia

Phase 2

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

CompletedNCT01527513

Bial - Portela C S.A.Partial Epilepsy

Start: 2010-08-31End: 2013-05-31Updated: 2014-10-24

Phase 3

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

CompletedNCT00988156

Bial - Portela C S.A.Partial Epilepsy in Children and Adolescents

Start: 2007-12-07End: 2017-08-24Updated: 2018-11-13

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

TerminatedNCT01124097

Bial - Portela C S.A.Post Herpetic Neuralgia

Start: 2010-09-30End: 2012-04-30Updated: 2014-04-07

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

TerminatedNCT01129960

Bial - Portela C S.A.Painful Diabetic Neuropathy

Start: 2010-11-30End: 2012-04-30Updated: 2014-07-18

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

CompletedNCT01162460

Bial - Portela C S.A.Epilepsy

Start: 2010-12-31End: 2016-09-30Updated: 2016-09-29

Related Papers

Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: <i><i>post hoc</i></i> analysis of a phase III trial and open-label extension study

Therapeutic Advances in Neurological Disorders2023-01-014 citations

Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures

Journal of Child Neurology2019-12-2612 citations

Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.

2018-01-2552 citations